Buscar

Estamos realizando la búsqueda. Por favor, espere...

Bortezomib: a new promising therapy for early antibody-mediated rejection after liver transplantation?

Abstract: Background: Tricuspid regurgitation (TR) after heart transplant (HT) can be an important complication depending on its etiology and severity. This study aims to analyze the prevalence of TR, the causes, and its evolution over time after HT. Methods: We performed a retrospective study of transplants performed between 2000 and 2019 in 2 centers (1009 patients). TR was grouped according to etiology: primary graft dysfunction (PGD), acute rejection, cardiac allograft vasculopathy (CAV), pulmonary hypertension, prolapse, endomyocardial biopsy complication (EMB), pacemaker (PM), and unclear etiology (TR not related to any process and for which no justification was found). Results: The prevalence of TR after HT was 19.8% (moderate: 13.2%, severe: 6.6%). Significant TR was more prevalent in the first months (month 1: 51%, month 3: 40%, month 6: 29%, 1 year: 24%). These results were related to the etiologies. Thus, in the first month, TR due to PGD is frequent and it is the only time when TR due to pulmonary hypertension appears. During the first 6 months, TR of unclear cause gains relevance, which tends to decrease over time. After 1 year, TR due to rejection predominates. After 5 years, TR is less frequent (< 10%) and related to long-term complications of HT, such as CAV, EMB, and those associated with PM. Conclusions: The prevalence of TR after HT is 19.8%. Prevalence and etiology change over time. Initially it is usually related to PGD, in the medium-term to rejection and in the long-term to CAV and procedures such as EMB and PM.

 Fuente: Transplantation Direct, 2019, 5(10), e492

 Editorial: Wolters Kluwer

 Año de publicación: 2019

 Nº de páginas: 2

 Tipo de publicación: Artículo de Revista

 DOI: 10.1097/TXD.0000000000000931

 ISSN: 2373-8731

 Url de la publicación: https://www.doi.org/10.1097/TXD.0000000000000931

Autoría

CHEDID, MARCIO F.